Disorders of ConsciousnessNCT02732288
Exploratory Study of Melatonin Induced Sleep Regularization in Severe Brain Injury
A study testing melatonin in people with Disorders of Consciousness, run by Rockefeller University at 1 site in United States.
Trial summary
Patients with severe brain injuries often have slow accumulating recoveries of function. In ongoing studies, we have discovered that elements of electrical activity during sleep may correlate with the level of behavioral recovery observed in patients. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Disorders of Consciousness
- What is being tested?
- melatonin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1 participants
- Where
- 1 siteUnited States
- Study dates
- May 2016to 19 Jun 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Subject's legally authorized representative must be fluent in English
- Subject must have been able to speak English prior to the brain injury occurrence
- Subject must have previously participated in the NSC-0764 study at Rockefeller University Hospital or New York Presbyterian-Cornell
- Subject must be diagnosed with a severe nonprogressive brain injury
- Subject must be medically stable
- Subject must be between 18 and 65 years of age
Show all 9Show fewer
- Male and female subjects accepted
- Subject must have previously participated in studies with EEG data that identify elements of sleep architecture (evidence of components of at least 1 of the following: Stage 2 features (e.g. spindles K complexes, or vertex waves) or stage 3 features (e.g. slow waves), including the NSC-0764 study, and this data must be available to the PI.
- HEALTHY VOLUNTEERS: case matched to the study population +/- 5 years; fluent in English; ability to sit still for several consecutive hours; must sleep normal hours consistently (approximately 10 pm - about 6 am) and not be a shift worker
Who cannot join
- Refractory generalized seizures
- Ventilator dependency
- Evidence of Alzheimer's Disease or dementia preinjury
- Currently taking melatonin
- Dialysis dependency
- Premorbid neuropsychiatric history (Axis I requiring prior hospitalization)
Show all 11Show fewer
- History of severe asthma (requiring hospitalization)
- Participation in any investigational trial within 30 days prior to enrollment in this study
- History of any sleep disorder or restless leg syndrome pre-injury
- Medical history, physical examination, or laboratory findings suggestive of any other medical or psychological condition that would, in the opinion of the principal investigator, make the candidate ineligible for the study
- HEALTHY VOLUNTEERS: current or past medical history of any neurological disease or cardiovascular disease, sleep disorder, teeth grinding or restless leg syndrome (RLS); taking any medications with any neurologic effects, any medical condition that disrupts sleep; participation in NSC-0764; Body Mass Index (BMI) > 30 kg/m2;
Trial locations and contacts
1 site in 1 country.
United States1 site
The Rockefeller University
New York, New York, 10065
About this study
Patients with severe brain injuries often have slow accumulating recoveries of function. In ongoing studies, we have discovered that elements of electrical activity during sleep may correlate with the level of behavioral recovery observed in patients. It is unknown whether such changes are causally linked to behavioral recovery. Sleep processes are, however, associated with several critical processes supporting the cellular integrity of neurons and neuronal mechanisms associated with learning and synaptic modifications. These known associations suggest the possibility that targeting the normalization of brain electrical activity during sleep may aid the recovery process. A well-studied mechanism organizing the pattern of electrical activity that characterizes sleep is the body's release of the substance melatonin. Melatonin is produced in the brain and released at a precise time during the day (normally around 8-10PM) to signal the brain to initiate aspects of the sleep process each day. Ongoing research by other scientists has demonstrated that providing a small dose of melatonin can improve the regular pattern of sleep and help aid sleep induction. Melatonin use has been shown to be effective in the treatment of time change effects on sleep ("jet lag") and mood disturbances associated with changes in daily light cues such as seasonal affective disorder. We propose to study the effects of melatonin administration in patients with severe structural brain injuries and disorders of consciousness. We will measure the patient's own timing of release of melatonin and provide a dose of melatonin at night to test the effects on the electrical activity of sleep over a three month period. In addition to brain electrical activity we will record sleep behavioral data and physical activity using activity monitors worn by the patients. Patient subjects in this study will be studied twice during the three month period in three day inpatient visits where they will undergo video monitoring and sampling of brain electrical activity using pasted electrodes ("EEG"), hourly saliva sampling for one day, and participation in behavioral testing.
Read the detailed description
Patients with severe brain injuries often have slow accumulating recoveries of function. Recently, the National Institute for Disability and Rehabilitation Research (NIDRR) published data on their long-term outcomes of over 9,000 patients, 400 of which suffered disorders of consciousness (Nakase-Richardson et al. 2012). Patients were followed for 1, 2, and 5 year outcomes and several important and unexpected results were obtained: a large majority of patients initially in minimally conscious state (MCS) continued to improve recovering consciousness within a year and recovery was demonstrated to continue at the 2 and 5 year timepoints for as many as 20% of patients. In these cases outcomes included vocational reentry. Other studies have confirmed that MCS recovery can occur over long-time periods and lead to good outcomes or significant recovery of meaningful cognitive function despite enduring convalesce in MCS (Luaute et al. 2010, Lammi et al. 2005).
In ongoing studies we have discovered that elements of electrical activity during sleep may correlate with the level of behavioral recovery observed in patients (Forgacs et al. 2014, Thengone et al. 2012). It is unknown, however, whether such changes are causally linked to behavioral recovery. Forgacs et al. 2014 showed a cross- sectional relationship between retention of key elements of sleep EEG architecture and behavioral level. Thengone et al. 2012 correlated longitudinal changes in sleep architecture and quantitative spectral measures with behavioral recovery in 4 patients with severe brain injuries. No studies, however, have used an instrumental causal design to address whether improvement in sleep architecture can be promoted in patients with severe brain injuries and if so, whether or not changes in wakeful behavioral level are causally linked to such instrumentally generated changes in sleep.
Sleep processes are associated with several critical processes supporting the cellular integrity of neurons and neuronal mechanisms associated with learning and synaptic modifications giving face validity to this approach. (Steriade, 1999; Tononi and Cirelli, 2012). For example, studies in healthy volunteers (Huber et al. 2004) have provided evidence that local spindle density changes are associated with learning of specific information over sleep periods and can be topographically related to cortical populations engaged by the wakeful learning process. Additional evidence indicates that recovery of spindles within the electrical architecture of sleep is more associated with recovery of motor function in stroke (Gottselig, 2002). Collectively, although only a limited number of studies exist there is a biological basis for improvement in sleep architecture to potentially drive recovery and reorganization of brain networks organizing wakeful behavior.
These known associations suggest the possibility that targeting the normalization of brain electrical activity during sleep may aid the recovery process. In fact, in one human subject studied here in our program, central thalamic deep brain stimulation (CT-DBS) applied beginning 20 years after severe traumatic brain injury (TBI) correlated with a normalization of sleep architecture beginning at the time after exposure to continuous DBS. These findings strongly suggest a link between increased driving of synaptic activity during the day and modification of sleep processes as this subject was only exposed to CT-DBS during daytime hours (Adams et al 2014). These findings improve the likelihood that there is a bi-directional causal relationship sleep dynamics and wakeful brain dynamics as linked to changes in behavior. Thus, the working hypothesis of the present study is that causal intervention to normalize sleep processes in patients with severe brain injuries may aid recovery of behavioral function.
A well-studied mechanism organizing the normal patterns of electrical activity that characterizes sleep is the body's release of the substance melatonin. Melatonin is produced in the brain and released at a precise time during the day (normally around 8-10PM) to signal the brain to initiate aspects of the sleep process each day (Dijk, 1997). It is possible to exogenously trigger and drive melatonin signaling of sleep processes and initiation of sleep via oral dosing of the agent (Lewy et al. 1992). Use of oral melatonin supplements is common for pre- treatment of expected travel delay sleep disturbances ("jet lag") and has been investigated in treatment of mood disorders (Lewy et al. 1996).
Thus, we propose to study the effects of melatonin administration in patients with severe structural brain injuries and disorders of consciousness. An existing, though small, literature supports the probable success of this study; in neurodegenerative patients melatonin supplementation has shown modest benefit in improving some cognitive and noncognitive symptoms (Riemersma-van der Lek et al. 2008). Pediatric patients with traumatic brain injuries have been considered for treatment with melatonin based on similar considerations (Keegan et al. 2013)
What will we do: We will measure the patient's own timing of release of melatonin and provide a dose of melatonin at a standard time at night (8PM) to test the effects on the electrical activity of sleep over a three month period. In addition to brain electrical activity, we will record sleep behavioral data and physical activity using activity monitors worn by the patients. Patient subjects in this study will be studied twice during the three month period in three day inpatient visits where they will undergo video monitoring and sampling of brain electrical activity using pasted electrodes ("EEG"), hourly saliva sampling for one day, and participate in behavioral testing.
Why are the risks proportionate? Melatonin is very safe and has a limited and known adverse effect profile (Buscemi at al. 2004) Melatonin does not accumulate and can be stopped. We will carefully monitor the first dose during an in-patient stay. Moreover, from an ethical frame there is in this study a clear intention to treat. If our hypothesis is supported patients will meaningfully improve in function.
- Conditions
- Disorders of Consciousness
- Being tested
- melatonin
- Medical subject headings
- Consciousness Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
melatoninDietary supplement
After measuring the subject's own timing of release of melatonin, subjects will be provided a dose of melatonin at 8pm to test the effects on the electrical activity of sleep, measured using electroencephalography. The same intervention will be given to healthy, non-brain injured controls.
| Study group | Role | What they receive |
|---|---|---|
| Melatonin, brain injured patients | Experimental | Melatonin 3mg, orally, at 8pm, daily for 3 months Receives: Dietary Supplement: melatonin |
| Healthy volunteers | Experimental | Melatonin 3mg, orally, at 8pm Receives: Dietary Supplement: melatonin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in in sleep/wake architecture following melatonin administration as assessed by time domain analysis of sleep EEG
Measured: baseline, 3 months
Secondary outcomes (3)
quantitative measures of EEG spectral content
Measured: baseline, 3 months
Changes in wakeful behavior level
Scales include: Coma Recovery Scale (CRS) and Confusion Assessment Protocol (CAP)
Measured: baseline, 3 months
Activity levels captured by Actigraph device
Actigraph is a wearable motion detector used to monitor and track activity and sleep.
Measured: baseline, 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2016 (estimated)
- Study startMay 2016
- Primary completion19 Jun 2018
- Study completion19 Jun 2018
Why it stopped: Interrupted by Covid-19
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (14)Papers the sponsor has linked to this study.
- Other trials for Disorders of ConsciousnessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 1 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rockefeller University
- Sponsor type
- University, hospital or other
- Collaborators
- Weill Medical College of Cornell University
- Responsible party
- Sponsor
- Investigators
- Nicholas Schiff, MD, Principal investigator, Weill Cornell Medical College/ Rockefeller University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02732288
- Sponsor's protocol ID
- NSC-0894
- Status last verified
- May 2023
- First submitted
- 4 Apr 2016
- Last updated
- 30 May 2023
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Luaute J, Maucort-Boulch D, Tell L, Quelard F, Sarraf T, Iwaz J, Boisson D, Fischer C. Long-term outcomes of chronic minimally conscious and vegetative states. Neurology. 2010 Jul 20;75(3):246-52. doi: 10.1212/WNL.0b013e3181e8e8df. Epub 2010 Jun 16.
PubMed 20554940Lammi MH, Smith VH, Tate RL, Taylor CM. The minimally conscious state and recovery potential: a follow-up study 2 to 5 years after traumatic brain injury. Arch Phys Med Rehabil. 2005 Apr;86(4):746-54. doi: 10.1016/j.apmr.2004.11.004.
PubMed 15827927Forgacs PB, Conte MM, Fridman EA, Voss HU, Victor JD, Schiff ND. Preservation of electroencephalographic organization in patients with impaired consciousness and imaging-based evidence of command-following. Ann Neurol. 2014 Dec;76(6):869-79. doi: 10.1002/ana.24283. Epub 2014 Oct 24.
PubMed 25270034Steriade M. Coherent oscillations and short-term plasticity in corticothalamic networks. Trends Neurosci. 1999 Aug;22(8):337-45. doi: 10.1016/s0166-2236(99)01407-1.
PubMed 10407416Tononi G, Cirelli C. Time to be SHY? Some comments on sleep and synaptic homeostasis. Neural Plast. 2012;2012:415250. doi: 10.1155/2012/415250. Epub 2012 Apr 29.
PubMed 22619736Huber R, Ghilardi MF, Massimini M, Tononi G. Local sleep and learning. Nature. 2004 Jul 1;430(6995):78-81. doi: 10.1038/nature02663. Epub 2004 Jun 6.
PubMed 15184907Nakase-Richardson R, Whyte J, Giacino JT, Pavawalla S, Barnett SD, Yablon SA, Sherer M, Kalmar K, Hammond FM, Greenwald B, Horn LJ, Seel R, McCarthy M, Tran J, Walker WC. Longitudinal outcome of patients with disordered consciousness in the NIDRR TBI Model Systems Programs. J Neurotrauma. 2012 Jan 1;29(1):59-65. doi: 10.1089/neu.2011.1829. Epub 2011 Aug 4.
PubMed 21663544Gottselig JM, Bassetti CL, Achermann P. Power and coherence of sleep spindle frequency activity following hemispheric stroke. Brain. 2002 Feb;125(Pt 2):373-83. doi: 10.1093/brain/awf021.
PubMed 11844737Dijk DJ, Cajochen C; New Collective Author. Melatonin and the circadian regulation of sleep initiation, consolidation, structure, and the sleep EEG. J Biol Rhythms. 1997 Dec;12(6):627-35. doi: 10.1177/074873049701200618.
PubMed 9406038Lewy AJ, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int. 1992 Oct;9(5):380-92. doi: 10.3109/07420529209064550.
PubMed 1394610Lewy AJ, Ahmed S, Sack RL. Phase shifting the human circadian clock using melatonin. Behav Brain Res. 1996;73(1-2):131-4. doi: 10.1016/0166-4328(96)00084-8.
PubMed 8788490Riemersma-van der Lek RF, Swaab DF, Twisk J, Hol EM, Hoogendijk WJ, Van Someren EJ. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA. 2008 Jun 11;299(22):2642-55. doi: 10.1001/jama.299.22.2642.
PubMed 18544724Keegan LJ, Reed-Berendt R, Neilly E, Morrall MC, Murdoch-Eaton D. Effectiveness of melatonin for sleep impairment post paediatric acquired brain injury: evidence from a systematic review. Dev Neurorehabil. 2014 Oct;17(5):355-62. doi: 10.3109/17518423.2012.741147. Epub 2013 Oct 8.
PubMed 24102301Buscemi N, Vandermeer B, Pandya R, Hooton N, Tjosvold L, Hartling L, Baker G, Vohra S, Klassen T. Melatonin for treatment of sleep disorders. Evid Rep Technol Assess (Summ). 2004 Nov;(108):1-7. doi: 10.1037/e439412005-001. No abstract available.
PubMed 15635761
Study at a glance
From the registry record, last updated by the sponsor on 30 May 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exploratory Study of Melatonin Induced Sleep Regularization in Severe Brain Injury
- ClinicalTrials.gov ID
- NCT02732288
- Acronym / sponsor ID
- NSC-0894
- Conditions
- Disorders of Consciousness
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Interrupted by Covid-19
- Enrolment
- 1 participants (actual)
- Lead sponsor
- Rockefeller UniversityUniversity, hospital or other
- Collaborators
- Weill Medical College of Cornell University
- Study start
- May 2016
- Primary completion
- 19 Jun 2018 (actual)
- Study completion
- 19 Jun 2018 (actual)
- First posted
- 8 Apr 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients with severe brain injuries often have slow accumulating recoveries of function. In ongoing studies, we have discovered that elements of electrical activity during sleep may correlate with the level of behavioral recovery observed in patients. It is unknown whether such changes are causally linked to behavioral recovery. Sleep processes are, however, associated with several critical processes supporting the cellular integrity of neurons and neuronal mechanisms associated with learning and synaptic modifications. These known associations suggest the possibility that targeting the normalization of brain electrical activity during sleep may aid the recovery process. A well-studied mechanism organizing the pattern of electrical activity that characterizes sleep is the body's release of the substance melatonin. Melatonin is produced in the brain and released at a precise time during the day (normally around 8-10PM) to signal the brain to initiate aspects of the sleep process each day. Ongoing research by other scientists has demonstrated that providing a small dose of melatonin can improve the regular pattern of sleep and help aid sleep induction. Melatonin use has been shown to be effective in the treatment of time change effects on sleep ("jet lag") and mood disturbances associated with changes in daily light cues such as seasonal affective disorder. We propose to study the effects of melatonin administration in patients with severe structural brain injuries and disorders of consciousness. We will measure the patient's own timing of release of melatonin and provide a dose of melatonin at night to test the effects on the electrical activity of sleep over a three month period. In addition to brain electrical activity we will record sleep behavioral data and physical activity using activity monitors worn by the patients. Patient subjects in this study will be studied twice during the three month period in three day inpatient visits where they will undergo video monitoring and sampling of brain electrical activity using pasted electrodes ("EEG"), hourly saliva sampling for one day, and participation in behavioral testing.
Detailed description
Patients with severe brain injuries often have slow accumulating recoveries of function. Recently, the National Institute for Disability and Rehabilitation Research (NIDRR) published data on their long-term outcomes of over 9,000 patients, 400 of which suffered disorders of consciousness (Nakase-Richardson et al. 2012). Patients were followed for 1, 2, and 5 year outcomes and several important and unexpected results were obtained: a large majority of patients initially in minimally conscious state (MCS) continued to improve recovering consciousness within a year and recovery was demonstrated to continue at the 2 and 5 year timepoints for as many as 20% of patients. In these cases outcomes included vocational reentry. Other studies have confirmed that MCS recovery can occur over long-time periods and lead to good outcomes or significant recovery of meaningful cognitive function despite enduring convalesce in MCS (Luaute et al. 2010, Lammi et al. 2005).
In ongoing studies we have discovered that elements of electrical activity during sleep may correlate with the level of behavioral recovery observed in patients (Forgacs et al. 2014, Thengone et al. 2012). It is unknown, however, whether such changes are causally linked to behavioral recovery. Forgacs et al. 2014 showed a cross- sectional relationship between retention of key elements of sleep EEG architecture and behavioral level. Thengone et al. 2012 correlated longitudinal changes in sleep architecture and quantitative spectral measures with behavioral recovery in 4 patients with severe brain injuries. No studies, however, have used an instrumental causal design to address whether improvement in sleep architecture can be promoted in patients with severe brain injuries and if so, whether or not changes in wakeful behavioral level are causally linked to such instrumentally generated changes in sleep.
Sleep processes are associated with several critical processes supporting the cellular integrity of neurons and neuronal mechanisms associated with learning and synaptic modifications giving face validity to this approach. (Steriade, 1999; Tononi and Cirelli, 2012). For example, studies in healthy volunteers (Huber et al. 2004) have provided evidence that local spindle density changes are associated with learning of specific information over sleep periods and can be topographically related to cortical populations engaged by the wakeful learning process. Additional evidence indicates that recovery of spindles within the electrical architecture of sleep is more associated with recovery of motor function in stroke (Gottselig, 2002). Collectively, although only a limited number of studies exist there is a biological basis for improvement in sleep architecture to potentially drive recovery and reorganization of brain networks organizing wakeful behavior.
These known associations suggest the possibility that targeting the normalization of brain electrical activity during sleep may aid the recovery process. In fact, in one human subject studied here in our program, central thalamic deep brain stimulation (CT-DBS) applied beginning 20 years after severe traumatic brain injury (TBI) correlated with a normalization of sleep architecture beginning at the time after exposure to continuous DBS. These findings strongly suggest a link between increased driving of synaptic activity during the day and modification of sleep processes as this subject was only exposed to CT-DBS during daytime hours (Adams et al 2014). These findings improve the likelihood that there is a bi-directional causal relationship sleep dynamics and wakeful brain dynamics as linked to changes in behavior. Thus, the working hypothesis of the present study is that causal intervention to normalize sleep processes in patients with severe brain injuries may aid recovery of behavioral function.
A well-studied mechanism organizing the normal patterns of electrical activity that characterizes sleep is the body's release of the substance melatonin. Melatonin is produced in the brain and released at a precise time during the day (normally around 8-10PM) to signal the brain to initiate aspects of the sleep process each day (Dijk, 1997). It is possible to exogenously trigger and drive melatonin signaling of sleep processes and initiation of sleep via oral dosing of the agent (Lewy et al. 1992). Use of oral melatonin supplements is common for pre- treatment of expected travel delay sleep disturbances ("jet lag") and has been investigated in treatment of mood disorders (Lewy et al. 1996).
Thus, we propose to study the effects of melatonin administration in patients with severe structural brain injuries and disorders of consciousness. An existing, though small, literature supports the probable success of this study; in neurodegenerative patients melatonin supplementation has shown modest benefit in improving some cognitive and noncognitive symptoms (Riemersma-van der Lek et al. 2008). Pediatric patients with traumatic brain injuries have been considered for treatment with melatonin based on similar considerations (Keegan et al. 2013)
What will we do: We will measure the patient's own timing of release of melatonin and provide a dose of melatonin at a standard time at night (8PM) to test the effects on the electrical activity of sleep over a three month period. In addition to brain electrical activity, we will record sleep behavioral data and physical activity using activity monitors worn by the patients. Patient subjects in this study will be studied twice during the three month period in three day inpatient visits where they will undergo video monitoring and sampling of brain electrical activity using pasted electrodes ("EEG"), hourly saliva sampling for one day, and participate in behavioral testing.
Why are the risks proportionate? Melatonin is very safe and has a limited and known adverse effect profile (Buscemi at al. 2004) Melatonin does not accumulate and can be stopped. We will carefully monitor the first dose during an in-patient stay. Moreover, from an ethical frame there is in this study a clear intention to treat. If our hypothesis is supported patients will meaningfully improve in function.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Melatonin, brain injured patients | Experimental | Dietary Supplement: melatoninMelatonin 3mg, orally, at 8pm, daily for 3 months |
| Healthy volunteers | Experimental | Dietary Supplement: melatoninMelatonin 3mg, orally, at 8pm |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Subject's legally authorized representative must be fluent in English
- Subject must have been able to speak English prior to the brain injury occurrence
- Subject must have previously participated in the NSC-0764 study at Rockefeller University Hospital or New York Presbyterian-Cornell
- Subject must be diagnosed with a severe nonprogressive brain injury
- Subject must be medically stable
Key exclusion criteria (11 listed)
- Refractory generalized seizures
- Ventilator dependency
- Evidence of Alzheimer's Disease or dementia preinjury
- Currently taking melatonin
- Dialysis dependency
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| melatoninAfter measuring the subject's own timing of release of melatonin, subjects will be provided a dose of melatonin at 8pm to test the effects on the electrical activity of sleep, measured using electroencephalography. The same intervention will be given to healthy, non-brain injured controls. | Dietary supplement | Healthy volunteers, Melatonin, brain injured patients |
Primary outcome
Changes in in sleep/wake architecture following melatonin administration as assessed by time domain analysis of sleep EEG
Time frame: baseline, 3 months
3 secondary outcomes
quantitative measures of EEG spectral content
Time frame: baseline, 3 months
Changes in wakeful behavior level
Time frame: baseline, 3 months
Activity levels captured by Actigraph device
Time frame: baseline, 3 months
Results and safety
The study was stopped early (reason given: Interrupted by Covid-19). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 May 2023.
- Background: PubMed 20554940Luaute J, Maucort-Boulch D, Tell L, Quelard F, Sarraf T, Iwaz J, Boisson D, Fischer C. Long-term outcomes of chronic minimally conscious and vegetative states. Neurology. 2010 Jul 20;75(3):246-52. doi: 10.1212/WNL.0b013e3181e8e8df. Epub 2010 Jun 16.
- Background: PubMed 15827927Lammi MH, Smith VH, Tate RL, Taylor CM. The minimally conscious state and recovery potential: a follow-up study 2 to 5 years after traumatic brain injury. Arch Phys Med Rehabil. 2005 Apr;86(4):746-54. doi: 10.1016/j.apmr.2004.11.004.
- Background: PubMed 25270034Forgacs PB, Conte MM, Fridman EA, Voss HU, Victor JD, Schiff ND. Preservation of electroencephalographic organization in patients with impaired consciousness and imaging-based evidence of command-following. Ann Neurol. 2014 Dec;76(6):869-79. doi: 10.1002/ana.24283. Epub 2014 Oct 24.
- Background: PubMed 10407416Steriade M. Coherent oscillations and short-term plasticity in corticothalamic networks. Trends Neurosci. 1999 Aug;22(8):337-45. doi: 10.1016/s0166-2236(99)01407-1.
- Background: PubMed 22619736Tononi G, Cirelli C. Time to be SHY? Some comments on sleep and synaptic homeostasis. Neural Plast. 2012;2012:415250. doi: 10.1155/2012/415250. Epub 2012 Apr 29.
- Background: PubMed 15184907Huber R, Ghilardi MF, Massimini M, Tononi G. Local sleep and learning. Nature. 2004 Jul 1;430(6995):78-81. doi: 10.1038/nature02663. Epub 2004 Jun 6.
- Background: PubMed 21663544Nakase-Richardson R, Whyte J, Giacino JT, Pavawalla S, Barnett SD, Yablon SA, Sherer M, Kalmar K, Hammond FM, Greenwald B, Horn LJ, Seel R, McCarthy M, Tran J, Walker WC. Longitudinal outcome of patients with disordered consciousness in the NIDRR TBI Model Systems Programs. J Neurotrauma. 2012 Jan 1;29(1):59-65. doi: 10.1089/neu.2011.1829. Epub 2011 Aug 4.
- Background: PubMed 11844737Gottselig JM, Bassetti CL, Achermann P. Power and coherence of sleep spindle frequency activity following hemispheric stroke. Brain. 2002 Feb;125(Pt 2):373-83. doi: 10.1093/brain/awf021.
- Background: PubMed 9406038Dijk DJ, Cajochen C; New Collective Author. Melatonin and the circadian regulation of sleep initiation, consolidation, structure, and the sleep EEG. J Biol Rhythms. 1997 Dec;12(6):627-35. doi: 10.1177/074873049701200618.
- Background: PubMed 1394610Lewy AJ, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int. 1992 Oct;9(5):380-92. doi: 10.3109/07420529209064550.
- Background: PubMed 8788490Lewy AJ, Ahmed S, Sack RL. Phase shifting the human circadian clock using melatonin. Behav Brain Res. 1996;73(1-2):131-4. doi: 10.1016/0166-4328(96)00084-8.
- Background: PubMed 18544724Riemersma-van der Lek RF, Swaab DF, Twisk J, Hol EM, Hoogendijk WJ, Van Someren EJ. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA. 2008 Jun 11;299(22):2642-55. doi: 10.1001/jama.299.22.2642.
- Individual participant dataSharing planned: No
Related trials for Disorders of Consciousness
RecruitingObservational study
Smartphone Enabled Detection of Cognitive Motor Dissociation in the ICU
Traumatic Brain Injury (TBI) Patients, Intracerebral Hemorrhage
Not yet recruiting
Miniature In-line Respirator
Brain Death, Respiration, Artificial
RecruitingObservational study
Genetic Markers of Cardiovascular Disease in Epilepsy
Epilepsy, Seizures
Recruiting
Comprehensive Assessment of Rehabilitation Experience Using the SAFE Scale
Caregiver Anxiety, Acquired Brain Injury
RecruitingObservational study
Sleep to Predict Recovery In Unconscious Patients With Acute Brain Injury
Traumatic Brain Injury (TBI) Patients, Intracerebral Hemorrhage (ICH)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nicholas Schiff, MD principal investigator
Weill Cornell Medical College/ Rockefeller University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing melatonin in people with Disorders of Consciousness, run by Rockefeller University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 30 May 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Interrupted by Covid-19). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in in sleep/wake architecture following melatonin administration as assessed by time domain analysis of sleep EEG (time frame: baseline, 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02732288, which also lists 14 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 May 2023.